TOP TEN perturbations for 1553336_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553336_a_at
Selected probe(set): 228961_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553336_a_at (228961_at) across 6673 perturbations tested by GENEVESTIGATOR:

R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.3134193
Number of Samples:4 / 4
Experimental R547 study 1 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-3.2840118
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.1130724
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.008667
Number of Samples:4 / 4
Experimental R547 study 3 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):2.8181133
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-2.737382
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

Huntington's disease study 16 (batch L) / Parkinson's disease study 32 (IPD)

Relative Expression (log2-ratio):2.6004066
Number of Samples:8 / 205
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control Parkinson's disease study 32 (IPD)
Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.597374
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

ulcerative colitis study 17 (5-ASA / AZA) / ulcerative colitis study 17 (5-ASA)

Relative Expression (log2-ratio):-2.5909653
Number of Samples:2 / 2
Experimental ulcerative colitis study 17 (5-ASA / AZA)
Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA) in combination with azathioprine (AZA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins.
Control ulcerative colitis study 17 (5-ASA)
Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins.

Huntington's disease study 16 (batch L) / control blood sample

Relative Expression (log2-ratio):2.5469484
Number of Samples:8 / 231
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control control blood sample
Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.